Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical company.
The business
Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical company. The Company is focused on developing targeted copper theranostics based on its SAR Technology Platform. It is progressing clinical trials with its approximately three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. Its lead product, SAR-bisPSMA, is progressing through over three clinical trials: one theranostic trial (SECuRE) and two Phase III diagnostic trials (CLARIFY and AMPLIFY). SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2). SAR-bisPSMA is developed for diagnosing, staging, and treating prostate cancer that expresses prostate-specific membrane antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer.
Small Caps Research
No research on Clarity Pharmaceuticals Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise CU6 based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Clarity Pharmaceuticals signs copper-64 isotope supply deal for use in prostate cancer trials
Clarity Pharmaceuticals (ASX: CU6) has signed a deal with the Australian Institute for Bioengineering and Nanotechnology (AIBN), located within the University of Queensland, for the supply of the copper-64 (cu-64) isotope used in the manufacture of diagnostic 64Cu-SAR-bisPSMA. Clarity will use the isotope to support the Phase III Clarify and Amplify registrational trials, an ongoing […]
Clarity Pharmaceuticals gains FDA fast-track status for advanced prostate cancer imaging drug
Oncology specialist Clarity Pharmaceuticals (ASX: CU6) has been granted fast-track designation by the US Food and Drug Administration (FDA) for the use of its 64Cu-SAR-bisPSMA in positron emission tomography imaging for prostate cancer. SAR-bisPSMA – a next-generation theranostic radiopharmaceutical with dual prostate-specific membrane antigen (PSMA)-targeting agents linked to Clarity’s SAR chelator technology – utilises copper […]
Clarity Pharmaceuticals begins phase II trial using SAR-Bombesin as prostate cancer diagnostic
Clarity Pharmaceuticals (ASX: CU6) has begun a phase II diagnostic trial for patients with prostate cancer using its Copper-64 SAR-Bombesin product in imaging scans. According to Clarity, SAR-Bombesin is a “highly targeted” wide-ranging cancer radiopharmaceutical. It has “broad cancer application” and works by targeting the gastrin-releasing peptide receptor (GRPr), which is present in a range […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.